Inicio>>Peptides>>Nemifitide diTFA

Nemifitide diTFA (Synonyms: INN 00835 diTFA)

Catalog No.GC39277

Nemifitide diTFA (INN 00835 diTFA) es un antidepresivo pentapéptido sintético con un potencial de acciÓn de inicio rÁpido.

Products are for research use only. Not for human use. We do not sell to patients.

Nemifitide diTFA Chemical Structure

Cas No.: 204992-09-6

Tamaño Precio Disponibilidad Cantidad
10mM (in 1mL Water)
423,00 $
Disponible
5mg
232,00 $
Disponible
10mg
417,00 $
Disponible
50mg
1.530,00 $
Disponible

Tel:(909) 407-4943 Email: sales@glpbio.com

Reseñas de cliente

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Nemifitide diTFA (INN 00835 diTFA) is a synthetic pentapeptide antidepressant with a potential for rapid onset of action[1]. Nemifitide diTFA is a peptide analog of melanocyte-inhibiting factor (MIF)[2]. Nemifitide diTFA can cross the blood-brain barrier[3].

[1]. Kelly JP, et al. The effect of treatment with a new antidepressant, INN 00835, on platelet serotonin uptake in depressed patients. J Affect Disord. 1999 Oct;55(2-3):231-5. [2]. Overstreet DH, et al. Antidepressant-like effects of a novel pentapeptide, nemifitide, in an animal model of depression. Psychopharmacology (Berl). 2004 Sep;175(3):303-9. [3]. Montgomery SA, et al. Efficacy and safety of 30 mg/d and 45 mg/d nemifitide compared to placebo in major depressivedisorder. Int J Neuropsychopharmacol. 2006 Oct;9(5):517-28.

Reseñas

Review for Nemifitide diTFA

Average Rating: 5 ★★★★★ (Based on Reviews and 16 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Nemifitide diTFA

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.